The CASP6 Knockout SK-OV-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-OV-3 human ovarian adenocarcinoma epithelial cell line, in which the CASP6 gene has been disrupted to establish a loss-of-function model. This polyclonal format preserves a range of editing outcomes, providing a heterogeneous population suited for pooled functional screens and analysis of population-level responses. CASP6 encodes a critical executioner caspase, and its ablation allows dissection of apoptotic and non-apoptotic functions without clonal bias.
SK-OV-3 is a well-characterized cell line established from the ascites of a 64-year-old female with ovarian adenocarcinoma, displaying a p53-null status and HER2 amplification, thereby recapitulating features of high-grade serous ovarian carcinoma. These cells are extensively utilized in cancer biology to investigate signal transduction, tumor progression, and therapeutic resistance, making them a clinically relevant host for studying caspase-dependent processes in a genomic context that compromises intrinsic apoptotic signaling.
CASP6 operates as a key executioner caspase, becoming activated through proteolytic cleavage by initiator caspases such as CASP8 and CASP9. Extrinsic pathway stimulation by death receptor ligands like FASL and TRAIL triggers CASP8, whereas intrinsic signaling releases cytochrome c, promoting APAF1 apoptosome-mediated activation of CASP9; Granzyme B (GZMB) also directly processes CASP6. Active CASP6 targets substrates including lamin A/C (LMNA and LMNC), PARP1, BID, and cytoskeletal proteins, orchestrating cellular demolition. It interacts with CASP3, CASP7, and is modulated by XIAP and its antagonist DIABLO/SMAC. Beyond apoptosis, CASP6 contributes to NF-kappaB signaling, pyroptosis, and neurodegeneration through processing of HTT and MAPT (tau).
In the SK-OV-3 background, CASP6 knockout is expected to hinder apoptotic execution, particularly lamin cleavage and nuclear disassembly, potentially altering sensitivity to chemotherapeutic agents. The p53-null, HER2-amplified setting permits dissection of p53-independent death pathways and evaluation of caspase-6-dependent drug resistance mechanisms. This model may reveal compensatory functions of other caspases and unmask non-apoptotic roles in ovarian cancer cell migration, invasion, or inflammatory responses.
This knockout cell population is suited for diverse experimental applications, including Western blotting for cleaved caspase-6 and caspase-3, caspase activity assays, annexin V/propidium iodide flow cytometry, PARP cleavage detection, and immunofluorescence for lamin A/C. Viability assays can profile chemosensitivity, supporting studies of apoptotic mechanisms, drug resistance, and non-canonical caspase functions in ovarian cancer and neurodegeneration. For further details, please contact Ascent Research.
